ORBCEL™ for Diabetic Kidney Disease (NEPHSTROM Trial)

About Orbsen Therapeutics

Orbsen Therapeutics is a private, clinical-stage biotech developing immunomodulatory cell therapies for serious conditions with high unmet need, including Diabetic Kidney Disease (DKD) and Acute Respiratory Distress Syndrome (ARDS). Its lead candidate, ORBCEL™, is a purified MSC therapy designed to target specific immune pathways driving inflammation and fibrosis. The company has advanced ORBCEL™ into Phase 2 clinical trials, supported by significant non-dilutive EU grant funding, and is actively fundraising to progress its pipeline. Orbsen operates from a new headquarters in Galway, positioning itself at the forefront of next-generation cell therapy.

Therapeutic Areas

Other Diabetic Kidney Disease (DKD) Drugs